Research programme: therapeutic agents - HanAll Biopharma

Drug Profile

Research programme: therapeutic agents - HanAll Biopharma

Alternative Names: HL 152B; HL 156Can; HL 176; HL004; HL010; HL011; HL020; HL021; HL022; HL023; HL024; HL025; HL026; HL027; HL030; HL034 (oral TPO agent) - HanAll; HL038; HL039; HL051; HL076; HL102; HL130; HL156; HL157 (oral monoclonal antibody) - HanAll Biopharma; HL160; HL177; HL178-TXNIP; HL178-TXNIP (negative regulator); metformin butyrate - HanAll BioPharma; Second-generation metformin products - HanAll Biopharma

Latest Information Update: 06 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HanAll Biopharma; Korea Research Institute of Chemical Technology
  • Developer HanAll Biopharma
  • Class Monoclonal antibodies; Proteins; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Cell adhesion molecule inhibitors; Gluconeogenesis inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Angina pectoris; Asthma; Atherosclerosis; Atopic dermatitis; Cancer; Diabetes mellitus; Hypertension; Inborn genetic disorders; Obesity; Parkinson's disease; Thrombocytopenia

Most Recent Events

  • 01 Dec 2014 HanAll in-licenses OmniRat®, OmniMouse® and OmniFlic® technology from Open Monoclonal Technology
  • 24 Aug 2012 Preclinical trials in Age-related macular degeneration in South Korea (Ophthalmic)
  • 24 Aug 2012 Preclinical trials in Autoimmune disorders in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top